Dr. Praneeth Baratam, MD
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Years since graduation
- 19
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 224
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
SC license 83526 -
Internal Medicine Physician
IL license 125056594 · PA license MD449181
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Musc Medical Center Charleston, SC
- Musc Health Columbia Medical Center Downtown Columbia, SC
- Musc Health Florence Medical Center Florence, SC
- Tidelands Georgetown Memorial Hospital Georgetown, SC
- Kershawhealth Camden, SC
Medical groups
- University Medical Associates of the Medical University of South Carol (1,668 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 224
- Services billed
- 598
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 131 | 86 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 86 | 34 |
| Established patient office or other outpatient visit, 30-39 minutes | 77 | 67 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 54 | 24 |
| New patient office or other outpatient visit, 60-74 minutes | 35 | 35 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 22 | 20 |
| Hospital discharge day management, more than 30 minutes | 18 | 18 |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | 17 | 13 |
| Telephone medical discussion with physician, 21-30 minutes | 15 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Charleston, SC | 61 |
| Posaconazole | 39 |
| Jakafi (ruxolitinib phosphate) | 29 |
| Idhifa (enasidenib mesylate) | 27 |
| Prevymis (letermovir) | 24 |
| Allopurinol Other prescribers in Charleston, SC | 21 |
| Hydroxyurea Other prescribers in Charleston, SC | 21 |
| Tibsovo (ivosidenib) | 17 |
| Ciprofloxacin Hcl Other prescribers in Charleston, SC | 17 |
| Venclexta (venetoclax) | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 55 payments worth $55,031 in total to this clinician.
| GlaxoSmithKline, LLC. | $17,540 |
|---|---|
| Rigel Pharmaceuticals, Inc. | $16,308 |
| Servier Pharmaceuticals LLC | $11,277 |
| Syndax Pharmaceuticals, Inc. | $5,416 |
| Novartis Pharmaceuticals Corporation | $3,988 |
| Alexion Pharmaceuticals, Inc. | $175 |
| Incyte Corporation | $125 |
| Genzyme Corporation | $104 |
| Compensation for services other than consulting (speaking, faculty) | $27,075 |
|---|---|
| Consulting Fee | $16,038 |
| Travel and Lodging | $8,483 |
| Food and Beverage | $1,724 |
| Honoraria | $1,713 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Rigel Pharmaceuticals, Inc. Apr 24, 2025 | Compensation for services other than consulting (speaking, faculty) REZLIDHIA · Acute Myeloid Leukemia | $6,028 |
| Rigel Pharmaceuticals, Inc. Jun 26, 2025 | Compensation for services other than consulting (speaking, faculty) REZLIDHIA · Acute Myeloid Leukemia | $4,384 |
| Syndax Pharmaceuticals, Inc. Sep 20, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $3,475 |
| GlaxoSmithKline, LLC. Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $2,900 |
| GlaxoSmithKline, LLC. Sep 8, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $2,900 |
| GlaxoSmithKline, LLC. Aug 25, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $2,900 |
| GlaxoSmithKline, LLC. Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $2,900 |
| Servier Pharmaceuticals LLC Nov 14, 2025 | Consulting Fee Tibsovo · Oncology | $2,800 |
| Servier Pharmaceuticals LLC Jun 6, 2025 | Consulting Fee Tibsovo · Oncology | $2,800 |
| Servier Pharmaceuticals LLC Sep 19, 2025 | Consulting Fee Tibsovo · Oncology | $2,800 |
All 33 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Syndax Pharmaceuticals, Inc. Dec 18, 2025 | Compensation for services other than consulting (speaking, faculty) REVUFORJ · HEMATOLOGY-ONCOLOGY | $1,193 |
| Novartis Pharmaceuticals Corporation Dec 3, 2025 | Consulting Fee SCEMBLIX · Oncology | $1,788 |
| Servier Pharmaceuticals LLC Nov 14, 2025 | Consulting Fee Tibsovo · Oncology | $2,800 |
| Servier Pharmaceuticals LLC Nov 14, 2025 | Travel and Lodging Tibsovo · Oncology · travel to Boston, MA | $441 |
| Servier Pharmaceuticals LLC Nov 14, 2025 | Travel and Lodging Tibsovo · Oncology · travel to Boston, MA | $364 |
| Servier Pharmaceuticals LLC Nov 14, 2025 | Travel and Lodging Tibsovo · Oncology · travel to Boston, MA | $165 |
| GlaxoSmithKline, LLC. Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $363 |
| Syndax Pharmaceuticals, Inc. Sep 20, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $3,475 |
| Syndax Pharmaceuticals, Inc. Sep 20, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to CHARLOTTE, NC · in-kind | $287 |
| Syndax Pharmaceuticals, Inc. Sep 20, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to CHARLOTTE, NC | $68.08 |
| Servier Pharmaceuticals LLC Sep 19, 2025 | Consulting Fee Tibsovo · Oncology | $2,800 |
| Servier Pharmaceuticals LLC Sep 19, 2025 | Travel and Lodging Tibsovo · Oncology · travel to Boston, MA | $500 |
| Servier Pharmaceuticals LLC Sep 19, 2025 | Travel and Lodging Tibsovo · Oncology · travel to Boston, MA | $92.00 |
| GlaxoSmithKline, LLC. Sep 8, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $2,900 |
| GlaxoSmithKline, LLC. Aug 25, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $2,900 |
| GlaxoSmithKline, LLC. Aug 21, 2025 | Travel and Lodging OJJAARA · ONCOLOGY · travel to Myrtle Beach, SC · in-kind | $1,400 |
| GlaxoSmithKline, LLC. Jul 29, 2025 | Travel and Lodging OJJAARA · ONCOLOGY · travel to Savannah, GA · in-kind | $1,073 |
| Rigel Pharmaceuticals, Inc. Jun 26, 2025 | Compensation for services other than consulting (speaking, faculty) REZLIDHIA · Acute Myeloid Leukemia | $4,384 |
| Rigel Pharmaceuticals, Inc. Jun 20, 2025 | Honoraria REZLIDHIA · Acute Myeloid Leukemia | $1,713 |
| Servier Pharmaceuticals LLC Jun 6, 2025 | Consulting Fee Tibsovo · Oncology | $2,800 |
| Servier Pharmaceuticals LLC Jun 6, 2025 | Travel and Lodging Tibsovo · Oncology · travel to Boston, MA | $558 |
| Servier Pharmaceuticals LLC Jun 6, 2025 | Travel and Lodging Tibsovo · Oncology · travel to Boston, MA | $269 |
| Servier Pharmaceuticals LLC Jun 6, 2025 | Travel and Lodging Tibsovo · Oncology · travel to Boston, MA | $202 |
| Rigel Pharmaceuticals, Inc. May 29, 2025 | Compensation for services other than consulting (speaking, faculty) REZLIDHIA · Acute Myeloid Leukemia | $2,055 |
| Novartis Pharmaceuticals Corporation May 22, 2025 | Consulting Fee SCEMBLIX · Oncology | $1,100 |
| Rigel Pharmaceuticals, Inc. Apr 24, 2025 | Compensation for services other than consulting (speaking, faculty) REZLIDHIA · Acute Myeloid Leukemia | $6,028 |
| Rigel Pharmaceuticals, Inc. Apr 10, 2025 | Travel and Lodging REZLIDHIA · Acute Myeloid Leukemia · travel to Greenville, SC · in-kind | $1,908 |
| GlaxoSmithKline, LLC. Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $2,900 |
| GlaxoSmithKline, LLC. Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $2,900 |
| Alexion Pharmaceuticals, Inc. Mar 27, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $175 |
| GlaxoSmithKline, LLC. Mar 20, 2025 | Travel and Lodging OJJAARA · ONCOLOGY · travel to Augusta, GA · in-kind | $1,156 |
| GlaxoSmithKline, LLC. Jan 30, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $1,452 |
| Novartis Pharmaceuticals Corporation Jan 14, 2025 | Consulting Fee SCEMBLIX · Oncology | $1,100 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 5 companies. The companies reported $245,557 in research payments for these studies, mostly to the institutions running them.
- A phase 1 study of SEACD70 in myeloid malignancies
Pfizer Inc. - A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplasti…
Taiho Oncology, Inc. - A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc. · Recruiting · NCT04988555 - A phase i, multicenter, open-label, dose-escalation and expansion, safety, pharmacokinetic, pharmacodynamic, and clinical activity study of orally administered AG-120 in subjects with advanced hematologic malignancies…
Servier Pharmaceuticals LLC - A phase 1, open-label, dose-escalation, and dose-expansion study to evaluate safety, tolerability, and clinical activity OFSNDX-5613IN combination with intensive chemotherapy in participants with newly diagnosed acute…
Syndax Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.